Lawsuit Filed by Treace Medical Concepts Over Alleged Patent Violations by Zimmer Biomet
**Treace Medical Confronts Alleged Patent Infringement in Bunion Correction Technologies**
Treace Medical Concepts, a pioneering medtech company specialising in the surgical treatment of bunions and related midfoot deformities, has taken legal action against Zimmer Biomet Holdings and Paragon 28. The lawsuit, filed in the United States District Court for the District of Delaware, alleges that the defendants have infringed upon four of Treace’s patents related to its Lapiplasty 3D Bunion Correction technologies.
The patents in question include U.S. Patent Nos. 12,102,368; 12,268,397; 12,268,428; and 12,274,481. Treace claims that these patents cover the unique Lapiplasty® system, a surgical platform that addresses the root cause of bunion deformities through a combination of specialized instruments, implants, and surgical techniques.
The lawsuit asserts that Zimmer Biomet and Paragon 28 are selling products—both tools and procedural methods—that too closely resemble the patented features of the Lapiplasty® system. The suit seeks both financial damages and a court order to halt the alleged infringing activities.
The timing of the lawsuit is significant, coming shortly after Zimmer Biomet’s $1.2 billion acquisition of Paragon 28 in April 2025. This acquisition may have expanded the scope of products that Treace considers infringing, as Paragon 28’s technologies could now be under the Zimmer Biomet umbrella.
Treace emphasises its robust patent portfolio—80 granted U.S. patents, 26 international patents, and over 150 pending applications—as evidence of its leadership in instrumented 3D bunion correction. The company’s founder and CEO, John Treace, stated that enforcing and defending these patents is crucial to protect their research investments and to continue driving innovation in the field.
If Treace prevails, Zimmer Biomet and Paragon 28 could face substantial financial penalties and potential restrictions on the sale of certain bunion correction products, which may affect their competitive position in the foot and ankle surgery market. Conversely, a victory for the defendants could embolden further competition and innovation in this surgical niche, but also raise questions about patent boundaries and the protection of surgical methods.
The case could influence future litigation involving similar technologies or methods, particularly regarding the enforceability of patents that cover both devices and procedural steps. The outcome could reshape the competitive landscape for bunion correction technologies and set important legal precedents for patent enforcement in the medical device industry.
**Table: Key Facts**
| Aspect | Details | |-----------------------|------------------------------------------------------------------------------------------| | Plaintiff | Treace Medical Concepts, Inc. | | Defendants | Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. | | Court | U.S. District Court of Delaware (Case No. 1:25-cv-00592) | | Patents in Question | U.S. Patent Nos. 12,102,368; 12,268,397; 12,268,428; 12,274,481 | | Technology | Lapiplasty® 3D Bunion Correction System (instruments, implants, surgical methods) | | Relief Sought | Financial damages and injunction against alleged infringing products | | Timing | Lawsuit filed shortly after Zimmer Biomet’s acquisition of Paragon 28 (April 2025)[1][5] | | Broader Context | Part of Treace’s strategy to protect its IP and maintain market leadership[1][2] |
In the context of the legal dispute over bunion correction technologies, Treace Medical Concepts claims that Zimmer Biomet Holdings and Paragon 28 have infringed upon their patents related to the Lapiplasty 3D Bunion Correction system, a medical-condition focused health-and-wellness innovation in the field of science. This patent infringement involves U.S. Patent Nos. 12,102,368; 12,268,397; 12,268,428; and 12,274,481, which cover medical plastics and other components used in the Lapiplasty medical device technology.
